Gene and Cell Therapy for Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 403
Special Issue Editor
Special Issue Information
Dear Colleagues,
Due to the heterogenous nature of cancer cells both among and within individual tumors, canonical cell and gene therapy approaches over the last few decades have focused on non-genetic approaches, such as enhancing cancer cell transduction, interfering with attributes of tumor physiology, and broad-based immunotherapy approaches. With the completion of The Cancer Genome Atlas Project, molecular characterization data are now publicly available for 33 different tumor types and contain more than 20,000 individual primary tumor samples. The availability of these data presents an intriguing and exciting opportunity for the broader cell and gene therapy community to identify common aberrant signaling networks in multiple tumor types and explore novel molecular-based targets for the development of potential therapeutics. This Special Issue welcomes all studies highlighting the potential for these new approaches and molecular targets for use in cancer gene and cell therapy applications.
Dr. Jacquelyn J. Bower
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer gene therapy
- cell therapy
- adeno-associated virus
- lentivirus
- immunotherapy
- oncolytic viruses
- cancer stem cells
- targeted therapy
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
